SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social activity and trading volume as investors discuss its technical strengths, including post-quantum security and real-world asset (RWA) potential. The community is actively debating the impact of recent leadership changes and the broader market's anticipation of upcoming regulatory clarity.

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project, with supporters actively rallying to increase its holder count and social media presence in hopes of driving a significant market cap expansion. The community is focused on organic growth and transparency, eagerly awaiting official charting status while coordinating promotional efforts across various platforms to maintain momentum.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating community buzz due to its ultra-low circulating supply and small market cap, which investors believe make it primed for significant price volatility and potential gains. Discussions are heavily focused on the hope for a resurgence in the NFT market, new exchange listings, and the token's historical ability to move rapidly with even minor increases in trading volume.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending as investors debate its long-term potential following a steep post-launch decline, with the community split between those accumulating at current price levels and others concerned about future token dilution. Supporters are actively discussing the project's high staking rewards and parallel processing technology as indicators of future value, while critics highlight low network activity and a challenging broader crypto market environment.

GraniteShares ETF Trust - GraniteShares 2x Long COIN Daily ETF

GraniteShares 2x Long COIN Daily ETF

CONL is trending as the community closely monitors the upcoming Senate Banking Committee markup of the CLARITY Act, viewing potential regulatory progress as a major catalyst for Coinbase and the broader crypto sector. Investors are also actively debating its long-term viability, with many using the stock's recent volatility to accumulate positions in anticipation of a potential rebound linked to Coinbase's earnings and Bitcoin's price trajectory.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending after reporting better-than-expected quarterly sales and earnings, with investors cheering the company's tightened focus on AI infrastructure and a raised full-year outlook. The community is actively discussing the company's potential as a 'quiet' AI turnaround story, though traders remain divided on whether the stock will maintain its momentum or face a pullback.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics ($GPCR) is trending sharply following positive Phase 2b clinical data for its oral GLP-1 drug, aleniglipron, which showed weight loss results that have fueled intense speculation regarding the company as a prime M&A target. Investors are actively debating the drug's efficacy and tolerability profile compared to competitors like Viking Therapeutics ($VKTX), with the community closely analyzing management's communication style and potential buyout interest from big pharma.

The ArcBlock project was created to create the first Blockchain ecosystem in the world. Develop and develop decentralized applications (DApp) according to objectives. ArcBlock, one of the ICO projects emerging in early 2018. Just launched on 3/1/2018, ArcBlock has quickly attracted the attention of technology as well as investors. ArcBlock brings great technological advancements that will open the third generation of blockchain applications.  Arcblock work by bridging the gap between different blockchains and their respective ecosystems has not been easy. There are some solutions which attempt to solve this problem, but it is evident there is plenty of room for competition in this regard. Building an open chain access layer capable of spanning multiple new and existing blockchains is a very interesting business model.  Building a new ecosystem meant to connect various chains will not be easy. As of right now, the team has completed its token sale, and the first public release candidate for the Open Chain Access Protocol will be released in Q3. Early 2019 will herald the introduction of more technical features and an Ethereum Blocklet prototype.

ArcBlock (ABT) is seeing heightened market activity and increased trading volume as community members speculate on potential AI integration and exchange listings, sparking both bullish price targets and skepticism regarding the project's utility. Conversations are dominated by long-term holders debating the legitimacy of recent partnership announcements and the token's ability to sustain upward momentum amid ongoing volatility.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

The Zebec Network (ZBCN) community is actively debating the project's long-term utility versus its recent price performance, with many holders focusing on institutional partnerships and the potential for a breakout following the conclusion of token unlocks. While skeptics highlight the high circulating supply and recent downward trends, advocates remain bullish on the network's integration into payroll systems and anticipated announcements at industry events.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos (XTZ) is facing intense division in online communities, with bearish traders predicting further downside while others discuss potential long-term catalysts like real-world asset tokenization and broader crypto adoption. The discourse is heavily polarized between skeptics calling for new lows and market participants monitoring technical momentum indicators for signs of a possible reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells.</li><li>The new collaboration comes as the company looks forward to clinical trials for the cell therapy.&nbsp;</li><li>ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies. &nbsp;</li></ul><blockquote>Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company.</blockquote>Cellipont is a cell therapy contract development and manufacturing organization. Its <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html">partnership</a> with Ernexa will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.<blockquote>"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."&nbsp; -Sanjeev Luther, CEO, Ernexa Therapeutics.</blockquote><h2 class="st-heading-2">About The Cell Therapy</h2>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Cellipont, it provides a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting, provided it is an allogeneic iMSC therapy using stem cells from a healthy donor rather than the patient themselves.ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies, the company said. The new collaboration comes as the company looks forward to clinical trials for the cell therapy.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock hitting a new high.<stembedurl>https://stocktwits.com/Roza11/message/634186263</stembedurl>Another, however, sees upcoming dilution.<stembedurl>https://stocktwits.com/Tradebub/message/634144629</stembedurl>ERNA stock is down by 58% this year and by 89% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bridgebio-shares-second-postive-late-stage-study-results-in-a-week-calcium-disorder-drug-trial-yields-positive-results/cLGZvEeR3DT">BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials 

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 

Equity

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

Shares of Ernexa Therapeutics (ERNA) fell 13% on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html">announced</a> a reverse stock split to regain compliance with the $1 minimum bid price required for continued listing on Nasdaq.The reverse stock split will be at a ratio of 1-for-15, effective June 12, 2025, at 12:01 a.m. Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on June 12.As a result of the reverse stock split, every 15 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock.No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares.As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares of common stock issued and outstanding on a split-adjusted basis.Ernexa also stated that it believes the reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs.Ernexa is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.On Stocktwits, retail sentiment around Ernexa improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_10_35_28_AM_png_969f4ebcc6.webp" alt="ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits" width="629" height="57"><figcaption>ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> is down by about 56% this year and by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tencent-music-expands-audio-empire-with-over-2-billion-ximalaya-merger/chl7VcFRbzk">Tencent Expands Audio Empire With $2.4B Ximalaya Merger: Retail Turns Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$0.2005
Prev Close	$0.2105
Open	$0.202
Dividend Yield	0.00%
50-Day Moving Average	$0.4636
Beta	0.89
Avg. Volume	1.35M
PE Ratio	-0.06

52-Week High	$4.02
52-Week Low	$0.184
Market Capitalization	$5.85M
EPS (Annual)	-$2.24
Price to Book	0.66
Revenue Per Employee	$0.00

ERNA
Ernexa Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ERNA News

ERNAErnexa Therapeutics Inc